The effect of recombinant α-interferon treatment on serum levels of hepatitis B virus-encoded proteins in man
✍ Scribed by Georg Hess; Wolfram Gerlich; Guido Gerken; Michael Manns; Thomas H. Hütteroth; Professor Karl-Hermann Meyer Zum Büschenfelde
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 488 KB
- Volume
- 7
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
et al. ( 12), or may decrease production of viral proteins.
📜 SIMILAR VOLUMES
Serum pregnancy-associated a2-glycoprotein (a2-PAG) levels were evaluated in a follow-up study of patients with hepatitis B virus (HBV) infection and compared with biochemical and virological parameters. In a study of 25 patients with acute hepatitis, an association was found between high a2- PAG va
Hepatitis B markers were studied in seven patients with reactivated liver disease. Reactivation of chronic type B hepatitis, as indicated by the reappearance of hepatitis B e antigen (HBeAg) in the serum, was characterised by the appearance of hepatitis B virus-DNA (HBV-DNA) in the serum. The expres
Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-a 2a (IFN) + prednisone (P). Four of 24 subsequent patients responded to IFN + P (combined response rate 19%). The median response duration was 8 months (3 to 30 months). The one-year sur
recently published data on human immunodeficiency vi-In about 30% to 40% of patients with chronic hepatitis rus type 1 (HIV-1) suggesting that both RNA viruses rep-C, treatment with recombinant interferon alfa (r-IFNa) licate continuously and highly productive in vivo. The causes a decrease of serum
The hepatitis C virus (HCV) nonstructural 5A (NS5A) protein has been implicated in the inherent resistance of HCV to interferon (IFN) antiviral therapy in clinical studies. Biochemical studies have demonstrated that NS5A interacts in vitro with and inhibits the IFN-induced, RNAdependent protein kina